These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 15736142)
61. 10 Years of End-of-Life Criteria in the United Kingdom. Bovenberg J; Penton H; Buyukkaramikli N Value Health; 2021 May; 24(5):691-698. PubMed ID: 33933238 [TBL] [Abstract][Full Text] [Related]
62. Economic evaluation of diagnostic technology. Methodological challenges and viable solutions. Sassi F; McKee M; Roberts JA Int J Technol Assess Health Care; 1997; 13(4):613-30. PubMed ID: 9489253 [TBL] [Abstract][Full Text] [Related]
63. Judgment under uncertainty; a probabilistic evaluation framework for decision-making about sanitation systems in low-income countries. Malekpour S; Langeveld J; Letema S; Clemens F; van Lier JB J Environ Manage; 2013 Mar; 118():106-14. PubMed ID: 23416987 [TBL] [Abstract][Full Text] [Related]
67. Decision analysis in evidence-based decision making. Tavakoli M; Davies HT; Thomson R J Eval Clin Pract; 2000 May; 6(2):111-20. PubMed ID: 10970005 [TBL] [Abstract][Full Text] [Related]
68. A proposal for a new social values research program and policy network. Littlejohns P; Yeung K; Clark S; Weale A J Health Organ Manag; 2012; 26(3):407-21. PubMed ID: 22852462 [TBL] [Abstract][Full Text] [Related]
69. Use of evidence in economic decision models: practical issues and methodological challenges. Cooper NJ; Sutton AJ; Ades AE; Paisley S; Jones DR; Health Econ; 2007 Dec; 16(12):1277-86. PubMed ID: 18034447 [TBL] [Abstract][Full Text] [Related]
70. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint. Chalkidou K; Culyer A; Naidoo B; Littlejohns P Health Econ; 2008 Mar; 17(3):441-8. PubMed ID: 17764094 [TBL] [Abstract][Full Text] [Related]
71. Single technology appraisals by NICE: are they delivering faster guidance to the NHS? Barham L Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204 [TBL] [Abstract][Full Text] [Related]
72. Benefits of probabilistic sensitivity analysis - a review of NICE decisions. Adalsteinsson E; Toumi M J Mark Access Health Policy; 2013; 1():. PubMed ID: 27226828 [TBL] [Abstract][Full Text] [Related]
73. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743 [TBL] [Abstract][Full Text] [Related]
74. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England. Marsh SE; Truter I Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):155-168. PubMed ID: 31056961 [No Abstract] [Full Text] [Related]
75. Standardizing economic appraisal of health technology in the European Community. Rovira J Soc Sci Med; 1994 Jun; 38(12):1675-8. PubMed ID: 8047926 [TBL] [Abstract][Full Text] [Related]
76. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Briggs AH; Ades AE; Price MJ Med Decis Making; 2003; 23(4):341-50. PubMed ID: 12926584 [TBL] [Abstract][Full Text] [Related]
77. NICE: guessing is not guidance. National Institute for Clinical Excellence. Poole-Wilson PA Heart; 2002 Jun; 87(6):510-2. PubMed ID: 12010929 [TBL] [Abstract][Full Text] [Related]
78. Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals. Srivastava T; Latimer NR; Tappenden P Pharmacoeconomics; 2021 Aug; 39(8):869-878. PubMed ID: 34008137 [TBL] [Abstract][Full Text] [Related]
79. Prioritisation of specialist health care services; not NICE, not easy but it can be done. Anderson P; Webb P; Groves S Health Policy; 2017 Sep; 121(9):978-985. PubMed ID: 28797706 [TBL] [Abstract][Full Text] [Related]